– Theriva received a $350,000 upfront payment at closing and is eligible for up to $91 million in regulatory and sales milestones, along with low single-digit royalties on net product sales – – Biossil to assume all responsibility and costs for future development and commercialization of the antibiotic- degrading enzyme portfolio – ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat c ...